Clinical trials
Hematologic Disease and Disorders clinical trials
Below are recruiting hematologic disease and disorders clinical trials, each written for real people, not researchers. We’re tracking 137 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05983952RecruitingPhase 2
Anti-CD38 antibody for APS with low platelets
This trial tests an anti-CD38 antibody in people with antiphospholipid syndrome (APS) who have very low platelet counts and haven't improved with steroids or other treatments. The goal is to see if it can safely raise platelet levels.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05995054RecruitingPhase 2
Obinutuzumab for chronic ITP that hasn't responded to steroids
This trial tests a drug called obinutuzumab for people with chronic ITP (low platelets) who haven't gotten better with steroids. The goal is to see if it can safely raise your platelet count.
TianjinAges 18 years+ - NCT06041620Recruiting
Gene-edited stem cell therapy for beta-thalassemia
This trial tests a new treatment that uses your own blood stem cells, edited with CRISPR technology, to reduce or eliminate the need for blood transfusions in people with beta-thalassemia.
Tianjin, Tianjin MunicipalityAges 3–35 - NCT06094881RecruitingPhase 2
Obinutuzumab for teens with immune thrombocytopenia
This trial tests a drug called obinutuzumab for teens aged 12–18 with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if obinutuzumab can safely raise platelet counts in those who haven't responded well to steroids or other treatments.
TianjinAges 12–18 - NCT06107582Recruiting
Long-term study of children with immune thrombocytopenia
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
TianjinAges 6–17 - NCT06168851RecruitingPhase 2
Anti-CD38 antibody for children with chronic ITP
This trial tests a new drug called anti-CD38 antibody for children and teens with chronic immune thrombocytopenia (ITP) whose platelet counts remain low despite other treatments. It may help increase platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 6–17 - NCT06219239Recruiting
Gene therapy for transfusion-dependent beta-thalassemia
This trial tests a new gene therapy for people with beta-thalassemia who need regular blood transfusions. It uses a virus to deliver a working gene into your own stem cells, then those cells are put back into your body to help your body make healthy red blood cells.
Tianjin, Tianjin MunicipalityAges 3–35 - NCT06254560RecruitingPhase 2
Rituximab for severe aplastic anemia with platelet transfusion problems
This study tests if the drug rituximab can help people with severe aplastic anemia whose bodies have stopped responding to platelet transfusions. It aims to see if rituximab can improve the body's ability to accept platelets again.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06281327RecruitingPhase 2
Avatrombopag for children with ITP switching from eltrombopag
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
TianjinAges 6–18 - NCT06387121RecruitingPhase 2
Low-dose chemo plus immune drugs for new B-ALL
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06481228Recruiting
TKI plus chemo and CAR-T for newly diagnosed Ph+ ALL
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
TianjinAges 18 years+ - NCT06622694RecruitingPhase 1
CD7 car-t cells for severe aplastic anemia
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06695741RecruitingPhase 2
Lower dose cyclophosphamide with standard therapy for severe aplastic anemia
This trial tests a lower dose of the chemotherapy drug cyclophosphamide combined with standard immune-suppressing medicines for people with newly diagnosed severe aplastic anemia. The goal is to see if this approach works as well as the usual treatment but with fewer side effects.
Tianjin, Tianjin MunicipalityAges 12 years+ - NCT06733610RecruitingPhase 1
CAR T-cell therapy for AIHA after 3 failed treatments
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06776510RecruitingPhase 1/Phase 2
NAD for immune thrombocytopenia study
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06783790RecruitingPhase 2
Avapritinib combo for relapsed AML after transplant
This trial tests a combination of three drugs (avapritinib, azacitidine, and venetoclax) for people whose acute myeloid leukemia (AML) has returned after a stem cell transplant. It targets a specific genetic change (C-KIT mutation) to try to stop the cancer from growing.
TianjinAges 18 years+ - NCT06797024Recruiting
Study of JY231 injection for tough nerve immune disorders
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Wuhan, HubeiAges 18–75 - NCT06799611RecruitingPhase 2
CM336 for immune thrombocytopenia (ITP)
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06855810RecruitingPhase 2/Phase 3
New treatment study for children with T-cell ALL
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
Hefei, AnhuiAges 1 month–18 years - NCT06926595RecruitingPhase 2
Stem cell transplant with low-dose chemo for graft-versus-host disease prevention
This trial tests a stem cell transplant using a reduced-intensity chemotherapy regimen and a low dose of a drug called cyclophosphamide after the transplant to help prevent graft-versus-host disease (GVHD), a common complication where donor cells attack the recipient's body. It is for people with certain blood cancers or bone marrow disorders who have a suitable donor.
Hershey, PennsylvaniaAges 18 years+ - NCT06936930Recruiting
Reproductive and Mental Health in Aplastic Anemia
This study looks at how aplastic anemia affects reproductive and mental health in adults. By understanding these connections, doctors can provide better support for your overall well-being.
Tianjin, Tianjin MunicipalityAges 18–40 - NCT07126782RecruitingEarly Phase 1
Gene-edited immune cells for AML after transplant
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
BeijingAges 18 years+ - NCT07152041RecruitingPhase 3
Pediatric Ph+ B-ALL treatment trial
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
Hefei, AnhuiAges 1 month–18 years - NCT07169500RecruitingPhase 1/Phase 2
CAR-T with or without stem cell transplant for young women with myeloma
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–50
Hear when a new Hematologic Disease and Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematologic disease and disorders?
- Yes. Clin2 currently lists 137 recruiting hematologic disease and disorders studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematologic disease and disorders trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematologic disease and disorders trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.